US equities |
TSLA $358.05 ▼-1.21% MU $896.94 ▼-3.68% NVDA $217.38 ▲+0.07% AAPL $345.53 ▲+1.03% SPCX $146.25 ▼-1.59% META $719.53 ▼-2.33% SNDK $1,333.37 ▼-4.41% AMD $541.92 ▼-3.61%
FinancialContent

Articles published by TNF Pharmaceuticals, Inc.

News headline image
TNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From TNF Pharmaceuticals, Inc.
Via Business Wire
Tickers TNFA
News headline image
TNF Pharmaceuticals Announces Closing of $7 Million Private Placement
From TNF Pharmaceuticals, Inc.
Via Business Wire
Tickers TNFA
News headline image
TNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications
From TNF Pharmaceuticals, Inc.
Via Business Wire
Tickers TNFA
News headline image
TNF Pharmaceuticals Announces Reverse Stock Split For Nasdaq Listing Compliance
From TNF Pharmaceuticals, Inc.
Via Business Wire
Tickers TNFA
News headline image
TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation
From TNF Pharmaceuticals, Inc.
Via Business Wire
Tickers TNFA
News headline image
TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease
From TNF Pharmaceuticals, Inc.
Via Business Wire
Tickers TNFA
News headline image
TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists
From TNF Pharmaceuticals, Inc.
Via Business Wire
Tickers TNFA
News headline image
TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development
From TNF Pharmaceuticals, Inc.
Via Business Wire
Tickers TNFA
News headline image
TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society’s Spring Meeting 2025
From TNF Pharmaceuticals, Inc.
Via Business Wire
Tickers TNFA
News headline image
TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia
From TNF Pharmaceuticals, Inc.
Via Business Wire
Tickers TNFA
News headline image
TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025
From TNF Pharmaceuticals, Inc.
Via Business Wire
Tickers TNFA
News headline image
TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor
From TNF Pharmaceuticals, Inc.
Via Business Wire
Tickers TNFA
News headline image
TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment
From TNF Pharmaceuticals, Inc.
Via Business Wire
Tickers TNFA
News headline image
TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion
From TNF Pharmaceuticals, Inc.
Via Business Wire
Tickers TNFA
News headline image
TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs
From TNF Pharmaceuticals, Inc.
Via Business Wire
Tickers TNFA
News headline image
TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference
From TNF Pharmaceuticals, Inc.
Via Business Wire
Tickers TNFA
News headline image
TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market
From TNF Pharmaceuticals, Inc.
Via Business Wire
Tickers TNFA
News headline image
TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline
From TNF Pharmaceuticals, Inc.
Via Business Wire
Tickers TNFA
News headline image
TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open Today
From TNF Pharmaceuticals, Inc.
Via Business Wire
Tickers MYMD